Show simple item record

dc.contributor.authorDoshi, Peter
dc.date.accessioned2017-05-24T13:47:18Z
dc.date.available2017-05-24T13:47:18Z
dc.date.issued2016-01-06
dc.identifier.citationDoshi, P. (2016). Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. BMJ, 352. DOI: 10.1136/bmj.h6849
dc.identifier.urihttp://hdl.handle.net/10713/6584
dc.descriptionAuthor discusses the question, "Will outsourcing determination of antibiotic effectiveness allow drug companies to influence prescribing?"
dc.description.urihttp://bmj.com/cgi/content/full/bmj.h6849?ijkey=ThkkcYTig2AlYyn&keytype=ref
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Groupen_US
dc.subjectNational Physicians Alliance FDA Task Forceen_US
dc.subject21st Century Cures Acten_US
dc.subject.lcshClinical and Laboratory Standards Instituteen_US
dc.subject.lcshUnited States. Food and Drug Administrationen_US
dc.subject.meshConflict of Interesten_US
dc.subject.meshMicrobial Sensitivity Tests--standardsen_US
dc.subject.meshOutsourced Services--standardsen_US
dc.titleDefining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testingen_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmj.h6849
dc.identifier.pmid26740024
dc.description.urinameClick here for the free full-text article on publisher's websiteen_US
refterms.dateFOA2019-02-19T18:15:22Z


Files in this item

Thumbnail
Name:
Doshi_DefiningAntibioticEffect ...
Size:
521.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record